Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Study Finds Bacterial Antigen Critical in Lethal Effects of Infection, Provides Clues for Therapy

By BiotechDaily International staff writers
Posted on 27 Aug 2013
Print article
A predominant molecular cause underlying lethal forms of infective endocarditis, sepsis, and kidney damage that often result from Staphylococcus aureus infection has been found, as well as indications for prevention and treatment therapies.

According to a study by a collaborative team at the University of Iowa (Iowa City, Iowa, USA) and the University of Minnesota (Minneapolis, MN, USA), the major superantigen (SAg) produced by S. aureus, staphylococcal enterotoxin C (SEC), is also a major cause of these severe conditions. Using the methicillin-resistant S. aureus (MRSA) strain MW2, the team showed that lethal sepsis, infective endocarditis and acute kidney infections in rabbits are critically dependent on high-level SAgs. SAgs, particularly SEC, were found to have a critical role in the development of all three conditions and that the association results from both superantigenicity and direct toxic effects on endothelial cells, the latter likely contributing to delayed endothelium healing. In contrast, the isogenic strain lacking SEC was found to be attenuated in virulence, and complementation with SEC restores disease production.

Infective endocarditis resulting from staph infection has a mortality rate of about 40%–50%, and about half of the surviving patients will suffer a stroke. The study showed that SEC not only over activates the immune system, but that this “excessive immune response is actually contributing very significantly to the destructive aspects of the disease, including capillary leakage, low blood pressure, shock, fever, destruction of the heart valves, and strokes that may occur in half of patients," said Patrick Schlievert, PhD, professor and chair of microbiology at the UI Carver College of Medicine. In addition to effects of excessive immune response, the SAgs also appear to have direct toxic effects, in part via endothelial cell stimulation.

Treatment therapeutics and prevention by vaccination are potential strategies for blocking these harmful effects. "We have high affinity molecules that neutralize superantigens and we have previously shown in experimental animals that we can actually prevent strokes associated with endocarditis in animal models. Likewise, we have shown that we can vaccinate against the superantigens and prevent serious disease in animals," said Prof. Schlievert. Also, low blood flow via the infection site appears to be one of the consequences of SEC’s action. The team found that increasing blood pressure by fluid replacement therapy reduced the formation of vegetations (the plaque-like meshwork made up of bacteria and host cell factors) on the heart valves and significantly protected from infective endocarditis, possibly also by washing away significant amounts of the superantigen molecule itself.

The study was published online August 20, 2013, in the American Society for Microbiology journal mBio.

Related Links:

University of Iowa
University of Minnesota
US National Institutes of Health



Print article

Channels

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.